Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Bibliographic Details
Title: Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
Authors: Andrew R. Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T. Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E. Coupland, Geetha Menon, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Renata Walewska, Scott Marshall, Christopher P. Fox, Peter Hillmen
Source: Haematologica, Vol 105, Iss 12 (2020)
Publisher Information: Ferrata Storti Foundation, 2020.
Publication Year: 2020
Collection: LCC:Diseases of the blood and blood-forming organs
Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5
Document Type: article
File Description: electronic resource
Language: English
ISSN: 0390-6078
1592-8721
Relation: https://haematologica.org/article/view/9646; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721
DOI: 10.3324/haematol.2019.230805
Access URL: https://doaj.org/article/53bc7354a2964c36992d8813be0e32a7
Accession Number: edsdoj.53bc7354a2964c36992d8813be0e32a7
Database: Directory of Open Access Journals
More Details
ISSN:03906078
15928721
DOI:10.3324/haematol.2019.230805
Published in:Haematologica
Language:English